News Releases

October 2, 2018
Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the appointment of Aoife Brennan , M.B., B.Ch., as president and chief executive officer of...
September 25, 2018
Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the Leerink Partners Roundtable Series on Rare...
September 4, 2018
Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)

– Data demonstrate statistically significant dose-dependent effects on SYNB1618 activity-associated biomarkers, supporting further development of SYNB1618 – – SYNB1618 dose established for treatment arm of ongoing Phase 1/2a study in patients with PKU; top-line data expected in mid-2019 – – Company

...
August 29, 2018
Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 29, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the H. C.

...
August 13, 2018
Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria
– Preclinical studies published in Nature Biotechnology identify key biomarkers of SYNB1618 activity in healthy animals and disease models – – Clinical data expected in 2018 from healthy volunteer cohorts of ongoing Phase 1/ 2a study of SYNB1618; data from patients with phenylketonuria (PKU) in...
August 8, 2018
Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates
- Data from Phase 1/2 studies of SYNB1618 and SYNB1020 expected by end of 2018 – – On track to advance first immuno-oncology program into IND-enabling studies in fourth quarter of 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2018-- Synlogic, Inc....
August 7, 2018
Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the 2018 Wedbush PacGrow Healthcare Conference at

...
June 25, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018

- Data highlight broad capabilities of Synlogic’s Synthetic Biotic platform to generate candidates for the potential treatment of cancer – - First program advancing into IND-enabling studies in 2H2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- Synlogic , Inc. ( Nasdaq: SYBX ), a

...
June 25, 2018
Synlogic Joins Russell 3000® Index

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the company’s addition to the Russell 3000® Index, following the Russell US Indices’ annual

...
June 11, 2018
Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria

– SYNB1618 currently being evaluated in a Phase 1/2a clinical trial in healthy volunteers and patients with Phenylketonuria (PKU); interim data expected in 2H 2018 – – Data presented in plenary session at ASM Microbe 2018 demonstrate lowering of blood phenylalanine (Phe) levels in an animal model

...
June 4, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®
– SYNB1020 currently being evaluated in a Phase 1b/2a clinical trial in patients with elevated ammonia due to cirrhosis; topline data expected by YE2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2018-- Synlogic , Inc. ( Nasdaq: SYBX ), a clinical-stage drug discovery and development company...
May 15, 2018
Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update

– Treated first subject in clinical trials of two Synthetic Biotic TM medicines, SYNB1020 and SYNB1618; both studies expected to generate data in 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to

...
Displaying 97 - 108 of 156